A new paradigm in skin health.
Effective and safe treatments that do not interfere with the immune system.
MoAskin Therapeutics is a biotechnology company founded to transform the treatment of chronic dermatological diseases. Our innovative approach addresses conditions like psoriasis from a completely new angle.
Our Mission
To offer new therapeutic solutions for skin diseases with significant social impact, improving the lives of millions of patients who currently lack safe and effective alternatives.
Our vision
To become the global benchmark in dermatological innovation by developing disruptive treatments that represent a true paradigm shift in the management of chronic skin diseases.
Technology
A new approach to skin diseases
Current treatments for diseases such as psoriasis and atopic dermatitis typically focus on modulating the immune system, which leads to limitations in efficacy, safety, and cost.
At MAskin Therapeutics we propose a radically different approach:
“Develop therapies specifically targeting cutaneous mechanisms (e.g., targets such as TREX2) to curb inflammation without suppressing the immune system.”
This opens the door to safer, more versatile, and more accessible treatments for millions of people around the world.
Team
Interdisciplinary Team
Leadership
Dr Ouldouz Ghashghaei
Drug Discovery Deputy
CSO
READ BIO | 
Dr Sara Preciado MBA
Business & Innovation
CEO
READ BIO |
Prof Concepció Soler
Immunology &
TREX2 Biology, CSO
READ BIO |
R&D Team
Dr Ouldouz Ghashghaei
Synthetic Chemistry
Prof Rodolfo Lavilla
Medicinal chemistry
Prof Francisco Ciruela
Pharmacology
Clinical dermatology
Montse Bonfill
Dermatitis
Dr Jaume Notario
Psoriasis
External advisors
Dr Joan Albertí
DMPK expert
Dr Marc Martinell
Dr Eulalia Baselga
Ichthyosis
Tecnology Transfer
Inma Iñiguez
FBG-UB
Laia Traveset
IDIBELL
Funding
1.5 millions Raised since 2020
News
Interesting posts related to our daily activity
Contact
Let’s start a conversation!
Reach out to our team with any questions, feedback, or partnership proposals.